22 Feb 2016 07:30
Fastnet Equity plc
("Fastnet" or the "Company")
22 February 2016
Potential Acquisition and Statement re Suspension
On 28 August 2015, Fastnet shareholders voted to adopt an investing policy focussed on acquiring companies or businesses in the healthcare sector particularly those in the biopharma sector. The Company now announces that it is in very advanced discussions with Amryt Pharmaceuticals DAC (the "Acquisition"). If the Acquisition proceeds, the enlarged group will become a late stage, specialty biopharmaceutical company and will constitute a reverse takeover in accordance with Rule 14 of the AIM Rules for Companies and Rule 14 of the ESM Rules for Companies.
Accordingly, the Company has requested that its ordinary shares be suspended from trading on AIM and ESM, with immediate effect, pending either publication of an admission document containing detailed information on the Acquisition or the termination of the proposed Acquisition.
A further announcement will be made in due course.
Enquiries:
Fastnet Oil & Gas plc | C/o FTI Consulting |
Harry Stratford, Non-Executive Director |
|
|
|
Shore Capital | +44 (0) 20 7408 4090 |
Nomad and Joint Broker |
|
Bidhi Bhoma, Edward Mansfield |
|
|
|
|
|
Davy | +353 (1) 679 6363 |
ESM Adviser and Joint Broker |
|
John Frain, Anthony Farrell |
|
|
|
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway |
|
AMYT.L (AMYT)